Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02453321 · ClinicalTrials.gov registry record · Phase 4

Continuous Adductor Canal Blocks Vs. Low Dose Femoral Nerve Blocks For Early Rehabilitation After Total Knee Arthroplasty

A Phase 4 study of Pain, Postoperative and Total Knee Arthroplasty (TKA), sponsored by Kevin King, DO.

Completed
Registry status
Phase 4
Development phase
62
Enrollment target
1
Study location

NCT02453321 is a Phase 4 study of Pain, Postoperative and Total Knee Arthroplasty (TKA) that has completed, run by Kevin King, DO. The registered enrollment target is 62 participants, below the 272-participant average among 108 other Pain, Postoperative trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02453321, a Phase 4 study of Pain, Postoperative and Total Knee Arthroplasty (TKA), has completed, sponsored by Kevin King, DO.

COMPLETED
Registry status
Phase 4
Development phase
62 participants
Enrollment target
1
Study location

Study Summary

Recently, several articles have suggested or reported that Adductor Canal Blocks (ACBs) offer adequate or equal analgesia and may promote better performance in early rehabilitation following Total Knee Arthroplasty (TKA) when compared to the more commonly used Femoral Nerve Block (FNB). A common feature of these studies has been the use of moderate to high concentration local anesthetics (e.g. 0.2% or 0.5% Ropivacaine respectively) which when injected by a large motor nerve will inevitably cause weakness. However, the practice at our institution has long been a continuous femoral nerve block (CFNB) with a lower concentration local anesthetic (0.0625% Bupivacaine). Over the past several years the investigators have performed several thousand CFNBs using this technique which has offered the advantage of minimal motor weakness and adequate analgesia. The primary goal of this study is to determine if our established practice of using a low concentration continuous FNB inserted about 5cm caudal to the groin crease (the apex of the femoral triangle) using a low infusion rate of 2ml/hr is comparable to the emerging practice of inserting a Continuous Peripheral Nerve Block (CPNB) in the anatomic adductor canal (AC) - infusing at 4ml/hr. A secondary goal is to study the effect of cumulative volume of local anesthetic infused through a FNB when at a rate of 2ml/hr compared to a rate of 4ml/hr in the 48-hour postoperative period. Definitions of the location of the adductor canal are debated heavily in literature, but they seem to agree that the middle 1/3 of the thigh contains the proximal AC while the distal 1/3 of the thigh contains the adductor hiatus - the terminal end of the AC. Our study will require placement of the continuous ACB no more distal than 20cm cephalad to the superior pole of the patella due to placement prior to surgery and the need to keep the dressing out of the operative field. The CACB catheter will also not be placed any more proximal than 20cm dista

Interventions

  • DRUG Bupivacaine
  • PROCEDURE Continuous Femoral Nerve Block
  • PROCEDURE Nerve Block, Continuous Adductor Canal
  • PROCEDURE Continuous Sciatic Nerve Block

Study Locations (1)

Pennsylvania

  • University of Pittsburgh Medical Center - Passavant Hospital - Pittsburgh

Trial Details

FieldValue
Enrollment Target 62 participants
Start Date 2015-06
Est. Completion 2016-08-31
Phase Phase 4

Sponsor

Kevin King, DO

1 total trials

What the Registry Record Tells You About NCT02453321

The ClinicalTrials.gov registry entry for NCT02453321 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 272-participant average among 108 other Pain, Postoperative trials with a reported enrollment target (77% lower). The listed sponsor is Kevin King, DO, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Pain, Postoperative appearing as the primary indexed condition, and to 4 interventions - of which Bupivacaine is the first listed.

NCT02453321 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02453321 about?

NCT02453321 is a clinical study titled "Continuous Adductor Canal Blocks Vs. Low Dose Femoral Nerve Blocks For Early Rehabilitation After Total Knee Arthroplasty". Recently, several articles have suggested or reported that Adductor Canal Blocks (ACBs) offer adequate or equal analgesia and may promote better performance in early rehabilitation following Total Knee Arthroplasty (TKA) when compared to the more commonly used Femoral Nerve Block (FNB). A common fea...

What is the current status of trial NCT02453321?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 62 participants. The study started on 2015-06. Estimated completion is 2016-08-31.

What conditions does trial NCT02453321 study?

This clinical trial studies the following conditions: Pain, Postoperative, Total Knee Arthroplasty (TKA).

What interventions are being tested in trial NCT02453321?

The interventions under investigation include: Bupivacaine (DRUG), Continuous Femoral Nerve Block (PROCEDURE), Nerve Block, Continuous Adductor Canal (PROCEDURE), Continuous Sciatic Nerve Block (PROCEDURE).

Who is sponsoring clinical trial NCT02453321?

This trial is sponsored by Kevin King, DO, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02453321 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain, Postoperative

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.